The pharmaceutical cold chain logistics industry presents four characteristics, the future opportunities and challenges coexist.

Pharmaceutical Network Market Analysis: As a branch of the logistics industry, the pharmaceutical cold chain refers to a systematic project between producers and users of refrigerated drug entities to meet the purposes of disease prevention, diagnosis and treatment.
recent years, with the deepening of national medical reform, "two-vote system" and other policies, China's pharmaceutical circulation scale is increasing, the layout of enterprises continue to increase, the pace of development of the pharmaceutical cold chain accelerated.
focus on pharmaceutical cold chain logistics sector related listed companies have been concerned recently, involving pharmaceutical cold chain logistics business related listed companies are attracting investors' attention.
For example, Canaan Technology recently replied on the interactive platform that the company's holding subsidiary Canaan Feiqi is a professional integrated solution provider of intelligent logistics systems, the main products include industrial automation production lines, intelligent three-dimensional warehouses, intelligent warehouse logistics systems, products can be widely used in medicine, tobacco, cold chain, express delivery, 3C electronics and new energy and other fields.
Group announced on the evening of August 10 that the company's third-party pharmaceutical cold chain logistics business revenue in January-June was about 900,000 yuan, accounting for 0.0076 percent of the company's main business revenue, accounting for a small proportion.
the company's third-party pharmaceutical cold chain logistics business in hand order amount is only 50,000 yuan, will not have a significant impact on the company's operating performance.
China Trade Logistics recently in the interactive platform in response to investors' questions, said that the company is not currently involved in cold chain logistics business, the company's cross-border logistics operations involving medical equipment, medicine, protective materials.
Junzheng Group on the evening of August 3, the risk that the company's current main business is chlor-alkali chemical business, does not involve blood products, biomedicine and cold chain logistics business.
the same evening, Akoma also issued a trading risk warning announcement, said that the company's asset structure and main business has not changed significantly, the main business income mainly from smart home appliances, commercial display cabinets and other industries.
it is learned that the company's biomedical cold chain industry is small, in 2019 the industry revenue of about 142 million yuan, accounting for about 2.40% of the company's main business income, accounting for a small proportion.
, the company is a cold chain solutions provider, not directly engaged in cold chain logistics and transportation business.
industry presents four characteristics of future opportunities and challenges coexist in recent years, China's pharmaceutical cold chain logistics industry has achieved rapid development.
According to the 2018-2023 China Pharmaceutical Logistics Industry Market Prospects and Investment Opportunities Research Report released by the China Business Industry Research Institute, china's total pharmaceutical logistics in 2017 was 3.02 trillion yuan.
according to the annual growth rate of 8%, it is expected that by 2020, China's total pharmaceutical logistics will reach 3.8 trillion yuan, and cold chain transport of drugs market size may reach 120 billion yuan.
August 13, 2020, at the 9th China Pharmaceutical Cold Chain Summit, industry sources said that 2020 is a turning point in the pharmaceutical cold chain industry, China's pharmaceutical cold chain logistics development road has a long way to go.
he pointed out that the industry presents four characteristics: First, China's total cost of pharmaceutical logistics has been steadily increasing;
the future, with the maturity of new biomedical technologies, as well as people's consumption upgrade, the demand for disease diagnosis and treatment is increasing, China's demand for pharmaceutical cold chain products will continue to expand, bringing huge room for development.
In the same time, 5G, artificial intelligence, blockchain, big data and other new technologies will continue to empower the pharmaceutical cold chain industry, to help the industry improve the level of automation, to achieve cost-effective, while the entire supply chain is more flexible and agile.
, in the context of the rapid development of pharmaceutical e-commerce, the pharmaceutical cold chain industry will be towards specialization, integration, standardization direction.
It is worth noting that at present, China's pharmaceutical cold chain logistics industry is in the early stage of development, the industry still has a small scale, scattered, disorderly phenomenon, while the logistics cost pressure is large, how to effectively reduce the cold chain transport costs in the future is a problem to be considered;
in the industry's view, the current pharmaceutical cold chain logistics industry competition pattern is more scattered, with the e-commerce industry, logistics industry and other giants to participate in the layout, or help to improve concentration, promote the development of the industry.
, large and medium-sized enterprises with many years of layout in this field have more development advantages.
.